The AGA Foundation awards grant to Dr. Michael Choi to further his research on carcinoid tumors
Bethesda, MD (June 25, 2009) The AGA Foundation for Digestive Health and Nutrition (FDHN) has named Michael Y. Choi , MD, the first recipient of the Mary Terese Hartzheim Award for Neuroendocrine Tumor Research. This new research award was created for young investigators interested in researching...Lexicon Initiates Phase 2 Clinical Trial of LX2931 in Patients With Rheumatoid Arthritis
...Phase 2 clinical trials, LX1031 for irritable bowel syndrome and LX1032 for carcinoid syndrome. Furthermore, LX4211 for diabetes has recently completed dosing i...n currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which wer...Carcinoid Cancer Foundation Sets Sights on Raising Awareness
...t the only cancers that catch victims by surprise. carcinoid cancer can go undetected for many years. Over 90% ...ectly diagnosed and treated for the wrong disease. carcinoid cancers are frequently diagnosed accidentally. carcinoid and related neuroendocrine tumors (NETs) grow slow...Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results
...future upon achievement of certain milestones related to NEBIDO(R) (in development for hypogonadism) and octreotide (in development for acromegaly and carcinoid syndrome), two of the Company's primary product candidates. The acquisition will be effected by means of a tender offer for all the outstanding shares...Indevus Pharmaceuticals Announces Definitive Merger Agreement With Endo Pharmaceuticals
...reotide implant (in development for acromegaly and carcinoid syndrome), two of Indevus' primary product candida...keting and sale for the treatment of acromegaly or carcinoid syndrome. The tender offer is expected to com...thogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. Abo...Endo Pharmaceuticals to Acquire Indevus Pharmaceuticals
... for hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. About Endo Pharmaceuticals Endo Pharmaceuticals is a specialty pharmaceutical company engaged in t...Saturated Fats Linked to Cancer of Small Intestine
...ective study to examine the association between meat and fat intake and cancer of the small intestine. During the study, 60 adenocarcinomas and 80 carcinoid tumors of the small intestine were diagnosed among the participants, and an elevated risk for these cancers was associated with saturated fat intake, ...Lexicon's Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
THE WOODLANDS, Texas, July 21 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has received orphan d...Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
...ood and Drug Administration (FDA), into a Phase 2a study in patients with carcinoid syndrome . Lexicon has identified the clinical trial sites for this study...n currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which wer...FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)
... for hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. Safe Harbor Statement This press release contains forward-looking statements within the mean...Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study
... for hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. PRO 2000 PRO 2000 (a naphthalene sulfonate polymer) is under development as a topical vaginal micr...Society of Interventional Radiology Foundation awards $191,000 in grants
...nu Gaur, Harvard Medical School, Boston, Mass., "Hepatic Arterial Chemoembolization (HACE), Yttrium-90 Radioembolization and Drug-eluting Bead-HACE in carcinoid Metastases to the Liver." ...Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
THE WOODLANDS, Texas, July 7 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has initiated a Phase 2 clinical trial of LX1032 , the...EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
Combination of Panzem(R) NCD and Avastin(R) May Slow Tumor Growth ROCKVILLE, Md., Jan. 28 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the pre...Delcath Systems Granted Third Orphan Drug Designation
... the drug melphalan for the treatment of neuroendocrine tumors metastatic to the liver. The trial is treating patients with pancreatic islet-cell and carcinoid tumors at the National Cancer Institute in Bethesda, Maryland. Commenting on this orphan-drug designation, Richard L. Taney, President and CEO of Del...Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
...scovering and developing breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by Lexicon's research team. Lexicon has used its proprietary ...Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
...naging gastrointestinal symptoms associated with carcinoid syndrome . The presentations will take place at ...X1032 is entering a Phase 2 study in patients with carcinoid syndrome. For more information on these pro... candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel s...Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
...scovering and developing breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by the company's research team. The company has used its prop...Indevus Pharmaceuticals Announces Release of 2008 Annual Report
... for hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. Contact: Michael W. Rogers EVP and Chief Financial Officer (781) 861-8444 Robin L....